20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Monte Rosa Therapeutics Inc (GLUE) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 173 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, GLUE reported $124M in revenue and ($39M) in net income.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Interactive charts & full statements → Open the GLUE valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $29M | $124M | $76M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $27M | $115M | $68M | ($6M) | ($9M) | ($2M) | ($1M) | $0M |
| Gross Margin % | 92.9% | 93.2% | 89.3% | — | — | — | — | — |
| Operating Income (EBIT) | ($182M) | ($54M) | ($81M) | ($143M) | ($112M) | ($73M) | ($28M) | ($8M) |
| Operating Margin % | -633.0% | -43.8% | -107.3% | — | — | — | — | — |
| Net Income | ($161M) | ($39M) | ($73M) | ($135M) | ($109M) | ($74M) | ($36M) | ($8M) |
| Net Margin % | -560.9% | -31.2% | -96.1% | — | — | — | — | — |
| EBITDA | ($156M) | ($31M) | ($62M) | ($129M) | ($101M) | ($72M) | ($27M) | ($8M) |
| Earnings Per Share (EPS) | $-2.18 | $-0.59 | $-0.98 | $-2.63 | $-2.30 | $-1.59 | $-0.82 | $-0.18 |
| Shares Outstanding (M) | 85M | 66M | 74M | 51M | 47M | 47M | 44M | 44M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $9M | $4M | $3M | $13M | $23M | $85M | $61M | $9M |
| Gross Profit | $9M | $2M | $3M | $13M | $23M | $85M | $61M | $9M |
| Gross Margin % | 100.0% | 51.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($49M) | ($50M) | ($50M) | ($33M) | ($16M) | $44M | $13M | ($27M) |
| Operating Margin % | -547.8% | -1188.5% | -1787.7% | -258.3% | -67.1% | 51.8% | 21.4% | -287.8% |
| Net Income | ($43M) | ($45M) | ($46M) | ($27M) | ($12M) | $47M | $13M | ($24M) |
| Net Margin % | -483.9% | -1057.1% | -1658.9% | -212.1% | -53.0% | 55.2% | 22.2% | -258.9% |
| EBITDA | ($41M) | ($42M) | ($44M) | ($28M) | ($9M) | $50M | $18M | ($22M) |
| Earnings Per Share (EPS) | $-0.51 | $-0.53 | $-0.70 | $-0.44 | $-0.20 | $0.57 | $0.22 | $-0.29 |
| Shares Outstanding (M) | 85M | 84M | 66M | 62M | 62M | 83M | 61M | 82M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($61M) | ($23M) | $42M | ($44M) | ($92M) | ($59M) | ($23M) | ($6M) |
| Capital Expenditures (CapEx) | $10M | $5M | $4M | $19M | $13M | $10M | $3M | $1M |
| Free Cash Flow (FCF) | ($71M) | ($27M) | $38M | ($63M) | ($105M) | ($69M) | ($26M) | ($8M) |
| FCF Margin % | -248.2% | -22.2% | 50.3% | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($81M) | ($37M) | ($43M) | $100M | ($35M) | ($45M) | $129M | ($21M) |
| Capital Expenditures (CapEx) | $7M | $2M | $1M | $1M | $2M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($88M) | ($39M) | ($44M) | $100M | ($36M) | ($47M) | $129M | ($21M) |
| FCF Margin % | -982.1% | -932.0% | -1574.3% | 781.5% | -157.0% | -55.4% | 212.3% | -232.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $696M | $449M | $439M | $304M | $342M | $366M | $49M | $11M |
| Cash & Cash Equivalents | $90M | $130M | $224M | $128M | $55M | $346M | $42M | $6M |
| Total Liabilities | $211M | $216M | $216M | $125M | $71M | $19M | $98M | $23M |
| Total Debt (Short + Long-Term) | $5M | $4M | $4M | $3M | $3M | $0M | $0M | $1M |
| Total Shareholders' Equity | $487M | $233M | $223M | $179M | $271M | $348M | ($49M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GLUE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms